Journal article
Intestinal Dysbiosis in, and Enteral Bacterial Therapies for, Systemic Autoimmune Diseases
Frontiers in immunology, Vol.11, pp.573079-573079
2020
DOI: 10.3389/fimmu.2020.573079
PMCID: PMC7655733
PMID: 33193357
Abstract
Recent studies have shown that a number of common autoimmune diseases have perturbations of their intestinal microbiome (dysbiosis). These include: Celiac Disease (CeD), Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Sjogren's Syndrome (SS), and Type 1 diabetes (T1D). All of these have intestinal microbiomes that are different from healthy controls. There have been numerous studies using animal models of single probiotics (monoclonal) or mixtures of probiotics (polyclonal) and even complete microbiota transfer (fecal microbial transfer-FMT) to inhibit or delay the onset of autoimmune diseases such as the aforementioned common ones. However, proportionally, fewer clinical trials have utilized monoclonal therapies or FMT than polyclonal therapies for treating autoimmune diseases, even though bacterial mono-therapies do inhibit the development of autoimmune diseases and/or delay the onset of autoimmune diseases in rodent models of those autoimmune diseases. In this review then, we review the previously completed and currently ongoing clinical trials that are testing bacterial therapies (FMT, monoclonal, and polyclonal) to treat common autoimmune dseases and discuss the successes in using bacterial monotherapies to treat rodent models of these common autoimmune diseases.
Details
- Title: Subtitle
- Intestinal Dysbiosis in, and Enteral Bacterial Therapies for, Systemic Autoimmune Diseases
- Creators
- Eric Marietta - Department of Dermatology, Mayo Clinic Rochester, Rochester, MN, United StatesAshutosh K Mangalam - Department of Pathology, University of Iowa, Iowa City, IA, United StatesVeena Taneja - Department of Immunology, Mayo Clinic Rochester, Rochester, MN, United StatesJoseph A Murray - Department of Immunology, Mayo Clinic Rochester, Rochester, MN, United States
- Resource Type
- Journal article
- Publication Details
- Frontiers in immunology, Vol.11, pp.573079-573079
- DOI
- 10.3389/fimmu.2020.573079
- PMID
- 33193357
- PMCID
- PMC7655733
- NLM abbreviation
- Front Immunol
- ISSN
- 1664-3224
- eISSN
- 1664-3224
- Publisher
- Switzerland
- Grant note
- P30 ES005605 / NIEHS NIH HHS R01 AI075262 / NIAID NIH HHS
- Language
- English
- Date published
- 2020
- Academic Unit
- Pathology; Iowa Neuroscience Institute
- Record Identifier
- 9984070226202771
Metrics
26 Record Views